CoChat

A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy

Rosati, Gerardo, Riccardi, Ferdinando, Tucci, Aniello, De Rosa, Patrizia, Pacilio, Giovanni · 2000 · Tumori Journal

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aims and background: To investigate the safety and efficacy of a paclitaxel and cisplatin regimen in a selected group of metastatic breast cancer patients with primary or acquired chemoresistance to anthracycline-based chemotherapy. Patients and methods: Thirty-eight consecutive women with metastatic breast cancer (PS ≤2) were entered in this phase II trial; all patients had been previously treated for metastatic disease with chemotherapy containing anthracyclines and had shown a progression of the disease during drug administration or after a clinical response lasting less than 6 months. Fifteen patients had received 2 or more chemotherapeutic regimens for advanced disease; 31 patients had ≥2 sites of metastatic disease. Paclitaxel (135 mg/m 2 ) was administered iv by a 3-hr infusion followed by iv infusion of cisplatin (75 mg/m 2 ) on day 1, every 3 weeks for 6 cycles. After the completion of the planned chemotherapy administration, 9 responsive patients continued to receive paclitaxel alone (175 mg/m 2 ) iv, on day 1, every 3 weeks, until disease progression or unacceptable toxicity. Results: A partial clinical response was recorded in 17 cases (45%; 95% CI, 30–64%). The median duration of overall response was 8 months; for the 9 responsive patients who continued treatment with paclitaxel alone, 4 had maintained the partial clinical response at the median follow-up of 24 months from the onset of therapy. The median time to progression was 6 months and median overall survival 8 months. Neurotoxicity was the most frequent adverse effect and caused treatment discontinuation in 5 cases for grade 3–4 paresthesia and/or an arthralgia/myalgia syndrome. Grade 3–4 neutropenia occurred in 16 patients (44%). Conclusions: Paclitaxel/cisplatin is an active regimen for the treatment of patients with metastatic breast cancer refractory to anthracycline-based chemotherapy. However, the cumulative neurotoxicity should limit the efficacy of prolonged paclitaxel monotherapy in responsive patients.

Overview

Integrity signals

Registry

Crossref · 10.1177/030089160008600306

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 14 references

Research works printed but not linked: 5

  1. Gianni L., 1994, Semin. Oncol., 21, 29
  2. Henderson I.C., 1987, Breast disease,, 428
  3. Horwitz S.B., 1993, J. Natl. Cancer Inst., 15, 15
  4. Perez T., 1995, Eur. J. Cancer, 31, 575
  5. Vermorken J.B., 1993, Eur. J. Cancer, 29, 435

Cited by

See all 17

Metadata

Authors
Rosati, G., Riccardi, F., Tucci, A., De Rosa, P., & Pacilio, G.
Affiliations
  • Ospedale San Carlo (IT)
  • Ospedale Antonio Cardarelli (IT)
  • Division of Medical Oncology, “A. Cardarelli'’ Hospital, Naples, Italy
Venue
Tumori Journal
Published
2000-05
Volume
86
Issue
3
Pages
207-210
ISSN
  • 0300-8916 (ISSN-L)
  • 2038-2529
OpenAlex
W2409903753
Cited by
17
References
14
Citations by year
2023: 2 · 2022: 2 · 2021: 1 · 2018: 3 · 2015: 1 · 2013: 1
FWCI
0.59
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Tumori Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords
metastatic breast cancer, paclitaxel, cisplatin, anthracycline resistance, combination chemotherapy, neurotoxicity, neutropenia, treatment response, overall survival
MeSH terms
Adult, Aged, Antibiotics, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Cisplatin, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Peripheral Nervous System Diseases, Survival Analysis, Treatment Outcome, Paclitaxel, Disease Progression, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy. https://app.cochat.ai/papers/10.1177/030089160008600306
The paper
Rosati, G., Riccardi, F., Tucci, A., De Rosa, P., & Pacilio, G. (2000). A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy. Tumori Journal. https://doi.org/10.1177/030089160008600306

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.